Darapladib is a Potent Lp-PLA2 Inhibitor for Atherosclerosis and Cancer Research
Darapladib is an orally active, selective and reversible Lp-PLA2 inhibitor, with an IC50 value of 0.25 nM.
TRV055, a G-protein-biased Agonist, is a Gq-biased Ligand of AT1R
The angiotensin II (Ang II) receptors, AT1R and AT2R, belong to the family of G protein-coupled receptors. Angiotensin II is the ligand of AT1R and AT2R. The two receptors are…
Ly93, an Oral Active SMS2 Inhibitor, Has Anti-Atherosclerotic Activity
The sphingomyelin synthase 2 (SMS2) is a potential target for pharmacological intervention in atherosclerosis. However, as far as now, reports about selective SMS2 inhibitors and their pharmacological activities were lacked.…